{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-005922","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.326654+00:00","generated_at":"2026-05-30T07:52:59.908923+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anika Therapeutics completes sale of Arthrosurface for $10M; plans to divest Parcus Medical","bullets":["Sold Arthrosurface to Phoenix Brio for $7M note plus up to $3M contingent consideration based on sales performance.","Announced intention to sell Parcus Medical sports medicine business as part of strategic review.","Focus shifts to core hyaluronic acid (HA) products and Regenerative Solutions, targeting $4B global market.","Piper Sandler serving as exclusive financial advisor for both the Arthrosurface sale and potential Parcus divestiture."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-005922","json":"https://secwatch.observer/filing/0001171843-24-005922.json","markdown":"https://secwatch.observer/filing/0001171843-24-005922.md","text":"https://secwatch.observer/filing/0001171843-24-005922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184324005922/0001171843-24-005922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184324005922/f8k_103024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:52:59.908923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}